Three groups with different routes of human immunodeficiency virus type 1 (HIV-1) transmission (homosexual men, hemophiliacs, and children) were studied for serum antibodies to a recombinant form of the HIV-1 protease using an enzyme-linked immunoassay. At 1 year after seroconversion, defined as the moment antibodies to HIV-1 proteins were first detected, 56% (34/61) of the homosexual men had antibodies to protease, and 2 years after seroconversion this percentage was 63% (24/38). Within this 2-year period these antibodies were no longer detected in 16% (9/56). A similar pattern was observed in 20 hemophiliacs who seroconverted after exposure to HIV-1-contaminated blood products. We found that 63% (160/255) of homosexual men in Centers for Disease Control stage II or III, 60% (9/15) of patients with acquired immunodeficiency syndrome (AIDS)-related complex, and 36% (14/39) of patients with AIDS had antibodies to protease. In 255 homosexual men in Centers for Disease Control stage II or III, antibodies to protease were significantly more frequently found in samples lacking HIV-1 antigen (P < 0.001) and possessing antibodies to HIV-1 core proteins (P < 0.001). Twenty-four persons who developed AIDS were studied longitudinally: 58% (14/24) had antibodies to protease 1 year before developing symptoms; 29% (7/24) showed a decline and 29% (7/24) showed a loss of antibodies to protease at the onset of symptoms. Within a group of 47 HIV-1-infected children, 90% (18/20) with a stable disease course were persistently protease antibody positive, versus 4 of 27 children (15%) with an unstable disease course (P = 0.0001). These data indicate that HIV-1 protease is expressed and antigenic in most HIV-1-infected individuals and that a decline or absence of antibodies to protease is strongly associated with unstable disease in children and AIDS in adults.
The human immunodeficiency virus type 1 (HIV-1) is the cause of the acquired immunodeficiency syndrome (AIDS; 4, 11, 20) . The humoral antibody response after HIV-1 infection is broad, showing antibodies to structural proteins (HIV-1 Ab) (envelope [3] . core [18] , and polymerase [21] ) as well as to several regulatory proteins, including the transactivator protein (Tat) (1), negative factor (Nef) (2) . virion infectivity factor (Vif) (2) , regulator of expression of virion proteins (Rev) (16) , and two proteins without a known function, Vpr and Vpu (22. 25) . Retroviral protease is an enzyme that cleaves Gag and Gag-polymerase precursor polyproteins into functional proteins of mature virus particles, and this processing is necessary for the infectivity of virus particles. In vitro mutagenesis of the protease-coding region of murine leukemia virus and HIV-1 resulted in protease-defective virus lacking infectivity (15, 17) . The translation product of the HIV-1 protease-coding region exhibits autoprocessing, resulting in a functional Il-kilodalton protein (8) . To what extent and at what time during natural infection this 11-kilodalton protease is expressed are not known.
Studies of HIV-1-infected individuals have shown a decline in antibodies to pl7f"Z-' and p24'"' core proteins (HIV-1 cAb) prior to development of symptoms of immunodeficiency (18, 19) . This decline in HIV-1 cAb is followed by the appearance of HIV-1 core antigens (HIV-1 cAg) in the serum (13) . A third but later determinant of disease progression is a decline in the amount of CD4t lymphocytes (9) . By using the Corresponding author. disappearance of HIV-1 cAb and persistent HIV-1 antigenemia, it was possible, in a prospective study, to predict the development of 80% of al AIDS cases (9) . However, even when a decline in the number of CD4+ lymphocytes was also taken into account, a small group with a grave short-term prognosis remained unidentified. To study the expression of HIV-1 protease in natural infection and in a search for additional prognostic markers, the antigenicity of HIV-1 protease was examined. A bacterially expressed protease was used as the antigen in an enzyme-linked immunoaissay (EIA) . Using this assay, we analyzed sera collected over time from several cohorts of HIV-1-infected individuals for antibodies to protease in relation to disease progression.
MATERIALS AND METHODS
Study population. Sera to be tested were obtained from four cohorts. The first group included participants in a prospective study on the prevalence and incidence of HIV infection and risk factors for AIDS. This study was (6) , all of these children were classified as P2 (symptomatic). The clinical condition of the children was rated stable or unstable by determining their pulmonary status, their neurological status, and the presence of opportunistic or major bacterial infections (10) .
None of the patients was receiving treatment with either zidovudine or interferon at the time serum samples were drawn.
Detection of HIV-1 Ab, HIV-1 cAg, and HIV-1 cAb. HIV-1 Ab were detected with two commercially available enzymelinked immunosorbent assays. Initially purified human T-cell lymphotropic virus type IIIB (HTLV-IIIB) was used as the antigen (Vironostika; Organon Teknika, Oss, The Netherlands). Later, bacterially produced recombinant HIV-1 Ag consisting of a mixture of viral core and envelope proteins were used (Abbott recombinant HIV-1 EIA; Abbott Laboratories, Chicago, Ill.) (7) . The moment of seroconversion was standardized by retrospectively testing all samples from seroconverters using the Abbott recombinant HIV-1 EIA. Seropositivity was confirmed by either immunoblotting or a commercially available recombinant EIA (Envacor; Abbott). Quantification of antibodies to core proteins in Envacor was achieved by comparing the optical density of a sample with the optical density of a serial twofold dilution of a reference serum. A sample showing fewer antibodies than the 1-to-16 dilution of the reference serum was considered negative. Serum samples were assayed for unbound HIV-1 cAg by using a sandwich-type EIA (Abbott) (12) . The assay is most sensitive for core protein p24 of HIV-1. By using a titration curve of the positive control, it is possible to quantitate the amount of antigen to a cutoff value of 50 pg/ml.
Detection of T-lymphocyte subsets. Peripheral blood mononuclear cells were isolated from heparinized venous blood by density gradient centrifugation on Ficoll-Hypaque. CD4à nd CD8 lymphocytes were enumerated by an indirect immunofluorescence technique using monoclonal antibodies (Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam) and a flow cytometry system (Epics-C; Coulter Electronics Ltd., Luton, United Kingdom). A low CD4' lymphocyte count was defined as CD4 lymphocyte numbers below 0.5 x 109/liter.
Detection of antibodies to HIV-1 protease. The protease was produced in Eschelirhia coli as a transnational fusion to the first 56 amino acids of E. coli galactokinase. The expression plasmid, designated PRO1 (8), consisted of a 272-base-pair DdcI restriction fragment (protease residues 1 to 92) from the BH10 clone of HTLV-IIIB inserted in the pOTSKF33 fusion vector (12) downstream and in-frame with the amino terminus of galactokinase. The recombinant fusion protein was produced and purified as previously described (1).
The presence of antibodies to protease was determined by using a direct enzyme-linked noncompetitive solid-phase immunoassay. Microdilution plates were coated with the recombinant protein using 1 pxg per well in 100 pl of phosphate-buffered saline (PBS) for 16 h at room temperature. After being coated, wells were washed six times with PBS-Tween 20 (0.1%, [vol/vol] ). Nonspecific binding sites were blocked by incubation for 1 h at 37°C with 4% normal goat serum in PBS-Tween 20, followed by another wash with PBS-Tween 20. Sera to be tested were diluted 1:100 in PBS-Tween 20 with 4% normal goat serum and incubated for 1 h at 37°C. After another washing step, horseradish peroxidase-conjugated goat anti-human immunoglobulin G (KPL, Gaithersburg, Md.) was added, diluted 1:500 in PBS-Tween 20 with 4% normal goat serum, and the wells were incubated for 1 h at 37°C. Bound antibodies were visualized using ortho-phenylenediamine, and the reaction was stopped with 1 N H2S04 after a coloring time of 10 min. Optical density was read at 450 nm (reference filter, 630 nm). Interassay variation was controlled by the inclusion on each plate of a protease-positive human sample in a serial dilution. Next, the value of the combination of HIV-1 cAg and either absence of HIV-1 cAb or absence of antibodies to HIV-1 protease was determined. Of 166 AIDS patients (cohort and hospital population) at diagnosis, 33 (20%) were both HIV-1 cAg negative and HIV-1 cAb positive. Thus, in 80% of the patients, HIV-1 cAb was not detectable and/or HIV-1 cAg was present (in 17 patients, the combination was not determined). Of 171 AIDS patients, 150 (88%/) were protease antibody negative and/or antigenemic (in 12 patients, the combination was not determined).
To study the development of antibodies to protease over time, serum samples from 47 American HIV-1-infected symptomatic children were tested. Within the group of 27 children with unstable disease course, several patterns were observed. Six children developed antibodies to protease during follow-up, four were persistently positive, seven lost antibodies. and ten were persistently negative. Of the group of 20 children with stable disease, 18 were persistently positive and 2 were persistently negative. Thus, 90%c (18/20) of children with stable disease were persistently protease antibody positive, versus only 15%c (4/27) of children with unstable disease (P = 0.0001). Of all 47 children, 12 died during follow-up; 9 of these 12 (75%) either lost antibodies or were persistently negative (3 were persistently positive). Within the group of 35 children still alive, 10 (28%) either lost antibodies or were persistently negative (P < 0.006). (10/24) were still negative, 29% (7/24) showed a decline in protease antibodies (determined by comparing optical densities), and 29% (7/24) had lost protease antibodies.
The results of this longitudinal study are comparable to the results of the transectional study on the larger groups of the cohort.
DISCUSSION
The antigenicity of protease in natural HIV-1 infection was studied, using a bacterially expressed HIV-1 protease gene product as the antigen in an EIA. A majority (70%) of HIV-1-infected individuals monitored over a period longer than 2 years after infection was found to have antibodies to HIV-1 protease. Some individuals failed to develop an antibody response to protease; no significant differences in optical densities of samples drawn before or after HIV-1 Ab seroconversion were found in these individuals (data not shown). Since viral protease is expressed and cleaved from a Gag-polymerase precursor (14) and some of the protease antibody-negative individuals showed the presence of core proteins (HIV-1 Ag) in their serum, one can assume that protease itself is exposed to the immune system.
Protease antibody negativity could be explained by variation in antigenic epitopes of protease among various HIV-1 strains, resulting in restricted reactivity, although this is not likely given the relatively low variation between sequenced HIV-1 protease genes. Indeed, comparing the amino acid sequences from the pol gene of three HIV-1 strains (HTLV-IIIB, LAV-1, and SF-2), a maximal difference of 4% was observed versus 15%c for the envelope gene (26 
